Chief Medical Officer · PMV Pharmaceuticals, Inc. (PMVP)

Leila Alland

A named executive officer of PMV Pharmaceuticals in every fiscal year CompBrief holds from FY2020 to FY2022. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2022

$2,490,079

Salary $469,758Stock awards $710,964

FY2021: $1,400,292

2nd of 3 named executive officers at PMV Pharmaceuticals by FY2022 total.

3 named officers on file for PMV Pharmaceuticals, FY2022

Leila Alland’s pay file — $29

  • 3 fiscal years of pay, line by line
  • 4 equity grants, each cited to its filing
  • PMVP’s disclosed peer group of 19 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how PMV Pharmaceuticals’s whole pay program stands against its peers

  • PMV Pharmaceuticals’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on PMVP→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 28, 2023 (DEF 14A).

Free

Get Leila Alland’s full pay file as a PDF — free

More than this page: up to 10 years of Leila’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Leila Alland compensation by year

PMV Pharmaceuticals Summary Compensation Table · all 3 fiscal years held
In US dollars, as PMV Pharmaceuticals reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2020FY2021FY2022
Salary$445,000$456,083$469,758
Bonus—$0$0
Stock awards—$0$710,964
Option awards$944,974$715,059$1,177,183
Non-equity incentive$184,675$229,150$132,174
Pension and deferred compensation—$0$0
All other—$0$0
Total$1,547,649$1,400,292$2,490,079

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: PMV Pharmaceuticals, Inc. DEF 14A filed April 28, 2023, accession 0001140361-23-021220, and prior-year filings. Open the filing on EDGAR.

How this page was built: the PMV Pharmaceuticals, Inc. filed document, accession 0001140361-23-021220. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2023.

$1.5M
$1.4M
$2.5M
FY20
FY21
FY22
SalaryNon-equity incentiveStock awardsOption awards

Equity holdings

unvested awards at FY2022 year-end
TypeUnvested unitsValue at year-endExercise price
RSU52,200$454,140—
Option118,463—$3.90
Option21,919—$28.33
Option82,650—$16.29

Per the Outstanding Equity Awards at Fiscal Year-End table in PMV Pharmaceuticals, Inc.'s FY2022 proxy; value at the fiscal year-end close, as the company printed it.

PMV Pharmaceuticals’s named executive officers, FY2022

as the company reported each
Named executive officerRoleFY2022 total
David MackPresident, Chief Executive Officer and Director$3,576,440
Leila Alland · this pageChief Medical Officer$2,490,079
Winston KungFormer Chief Operating Officer and Chief Financial Officer$1,768,476

The full PMV Pharmaceuticals compensation record

free company brief

This page is one person within PMV Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the PMV Pharmaceuticals proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are PMV Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Leila Alland's compensation dossier · One-time report. No refunds.